Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Hdl Handle:
http://hdl.handle.net/10147/208929
Title:
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
Authors:
Moreau, Isabelle; Levis, John; Crosbie, Orla; Kenny-Walsh, Elizabeth; Fanning, Liam J
Affiliation:
Molecular Virology Diagnostic & Research Laboratory, Department of Medicine,, Clinical Sciences Building, Cork University Hospital, Cork, Ireland., i.moreau@ucc.ie
Citation:
Virol J. 2008 Jul 9;5:78.
Journal:
Virology journal
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208929
DOI:
10.1186/1743-422X-5-78
PubMed ID:
18613968
Abstract:
Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated alpha2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20-30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF). Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be use to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis.
Language:
eng
MeSH:
Adult; Antiviral Agents/administration & dosage/*therapeutic use; Drug Therapy, Combination; Evolution, Molecular; Female; *Genetic Variation; Genotype; Hepacivirus/*classification/drug effects/genetics; Hepatitis C, Chronic/*drug therapy/virology; Humans; Interferon-alpha/administration & dosage/*therapeutic use; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols/administration & dosage/*therapeutic use; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin/administration & dosage/*therapeutic use; Sequence Analysis, DNA; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication
ISSN:
1743-422X (Electronic); 1743-422X (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMoreau, Isabelleen_GB
dc.contributor.authorLevis, Johnen_GB
dc.contributor.authorCrosbie, Orlaen_GB
dc.contributor.authorKenny-Walsh, Elizabethen_GB
dc.contributor.authorFanning, Liam Jen_GB
dc.date.accessioned2012-02-03T15:07:41Z-
dc.date.available2012-02-03T15:07:41Z-
dc.date.issued2012-02-03T15:07:41Z-
dc.identifier.citationVirol J. 2008 Jul 9;5:78.en_GB
dc.identifier.issn1743-422X (Electronic)en_GB
dc.identifier.issn1743-422X (Linking)en_GB
dc.identifier.pmid18613968en_GB
dc.identifier.doi10.1186/1743-422X-5-78en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208929-
dc.description.abstractPre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated alpha2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20-30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF). Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be use to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAntiviral Agents/administration & dosage/*therapeutic useen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshEvolution, Molecularen_GB
dc.subject.meshFemaleen_GB
dc.subject.mesh*Genetic Variationen_GB
dc.subject.meshGenotypeen_GB
dc.subject.meshHepacivirus/*classification/drug effects/geneticsen_GB
dc.subject.meshHepatitis C, Chronic/*drug therapy/virologyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshInterferon-alpha/administration & dosage/*therapeutic useen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshMolecular Sequence Dataen_GB
dc.subject.meshPhylogenyen_GB
dc.subject.meshPolyethylene Glycols/administration & dosage/*therapeutic useen_GB
dc.subject.meshRecombinant Proteinsen_GB
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_GB
dc.subject.meshRibavirin/administration & dosage/*therapeutic useen_GB
dc.subject.meshSequence Analysis, DNAen_GB
dc.subject.meshTreatment Failureen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshViral Loaden_GB
dc.subject.meshVirus Replicationen_GB
dc.titleCorrelation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.en_GB
dc.contributor.departmentMolecular Virology Diagnostic & Research Laboratory, Department of Medicine,, Clinical Sciences Building, Cork University Hospital, Cork, Ireland., i.moreau@ucc.ieen_GB
dc.identifier.journalVirology journalen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.